Pfizer Pipeline

May 9, 2013

Disclaimer

- As some programs are still confidential, some candidates may not be identified in this list. In these materials, Pfizer discloses Mechanism of Action (MOA) information for candidates from Phase 3 through regulatory approval. With a view to expanding the transparency of our pipeline, Pfizer is including new indications or enhancements, which target unmet medical need or represent significant commercial opportunities. The information contained on these pages is correct as of May 9, 2013.

- Visit Pfizer.com/pipeline, Pfizer's online database where you can learn more about our portfolio of new medicines and find out more about our Research and Development efforts around the world.

Table of Contents

Pfizer Pipeline Snapshot	4
Cardiovascular & Metabolic Diseases	5
Inflammation & Immunology	6
Neuroscience & Pain	7
Oncology	8
Vaccines	9
Other Areas of Focus (including Biosimilars and Rare Diseases)	10
Projects Discontinued Since Last Update	11

Pfizer Pipeline Snapshot



Pipeline represents progress of R&D programs as of May 9, 2013

Included are 56 NMEs, 16 additional indications, plus 2 biosimilars

Recent Approval

- **Bosulif** for Treatment of Previously Treated Chronic Myelogenous Leukemia (EU)



Pipeline represents progress of R&D programs as of February 28, 2013

Included are 61 NMEs, 15 additional indications, plus 2 biosimilars

Recent Approval

- **Eliquis** for Prevention of Stroke and Systemic Embolism in patients with Nonvalvular Atrial Fibrillation (U.S./EU)

Pfizer Pipeline – May 9, 2013

Therapeutic Area	Compound Name	Mechanism of Action (Phase 3 through regulatory approval)	Indication	Phase
Cardiovascular and Metabolic Diseases	Eliquis (apixaban)	Factor Xa Inhibitor	Venous Thromboembolism Prevention (U.S.)	Phase 3
	Eliquis (apixaban)	Factor Xa Inhibitor	Venous Thromboembolism Treatment	Phase 3
	ertugliflozin (PF-04971729)		Diabetes Mellitus-Type 2	Phase 2
	RN316 (PF-04950615)		Hypercholesterolemia (Biologic)	Phase 2
	PF-04937319		Diabetes Mellitus-Type 2	Phase 2
	PF-00489791		Diabetic Nephropathy	Phase 2
	PF-04634817		Diabetic Nephropathy	Phase 2
	PF-05231023		Diabetes Mellitus-Type 2 (Biologic)	Phase 1
	PF-05175157		Diabetes Mellitus-Type 2	Phase 1
	RN317 (PF-05335810)		Hypercholesterolemia (Biologic)	Phase 1
	PF-06282999		Acute Coronary Syndrome	Phase 1

New Molecular Entity

New Indication or Enhancement

Pfizer Pipeline – May 9, 2013 (cont'd)

Therapeutic Area	Compound Name	Mechanism of Action (Phase 3 through regulatory approval)	Indication	Phase
Inflammation and Immunology	tofacitinib	JAK Inhibitor	Rheumatoid Arthritis (EU)	Registration
	Xeljanz (tofacitinib)	JAK Inhibitor	Psoriasis (Oral)	Phase 3
	Xeljanz (tofacitinib)	JAK Inhibitor	Ulcerative Colitis	Phase 3
	PF-04171327		Rheumatoid Arthritis	Phase 2
	PF-05285401		Ulcerative Colitis (Biologic)	Phase 2
	anrukinzumab (IMA-638)		Ulcerative Colitis (Biologic)	Phase 2
	PF-00547659		Crohn's Disease, Ulcerative Colitis (Biologic)	Phase 2
	PF-04236921		Crohn's Disease, Lupus (Biologic)	Phase 2
	PH-797804		Chronic Obstructive Pulmonary Disease	Phase 2
	▶ PD-0360324		▶ Sarcoidosis, *Lupus (Biologic)	Phase 2
	PF-06473871 (EXC 001)		Dermal Scarring	Phase 2
	Xeljanz (tofacitinib)		Psoriatic Arthritis, Ankylosing Spondylitis, Psoriasis (Topical), Crohn's Disease	Phase 2
	Dekavil		Rheumatoid Arthritis (Biologic)	Phase 1
	PF-03715455		Chronic Obstructive Pulmonary Disease	Phase 1
	PF-06342674		Diabetes Mellitus-Type 1 (Biologic)	Phase 1

New Molecular Entity

New Indication or Enhancement

▶ Indicates that the project is either new or has progressed in phase since the previous portfolio update of Pfizer.com

* Note: Additional indications in Phase 1

Pfizer Pipeline – May 9, 2013 (cont'd)

Therapeutic Area	Compound Name	Mechanism of Action (Phase 3 through regulatory approval)	Indication	Phase
Neuroscience & Pain	Celebrex	COX-2	Chronic Pain (U.S.)	Registration
	Remoxy	Mu-type opioid receptor (MOR-1) Agonist	Moderate to Severe Pain (U.S.)	Registration
	ALO-02 Oxycodone-naltrexone core	Mu-type opioid receptor (MOR-1) Agonist	Moderate to Severe Pain	Phase 3
	Lyrica	Alpha-2 Delta Ligand	Peripheral Neuropathic Pain	Phase 3
	Lyrica	Alpha-2 Delta Ligand	CR (once a day dosing)	Phase 3
	tanezumab	Nerve Growth Factor Inhibitor	OA Signs and Symptoms (Biologic) (on clinical hold)	Phase 3
	PF-05212377 (SAM-760)		Alzheimer's Disease	Phase 2
	PF-03049423		Stroke Recovery	Phase 2
	tanezumab		Cancer Pain (Biologic)	Phase 2
	PF-05089771		Chronic Pain	Phase 1
	PF-05236812 (AAB-003)		Alzheimer's Disease (Biologic)	Phase 1
	PF-04958242		Schizophrenia	Phase 1
	PF-06305591		Chronic Pain	Phase 1
	PF-06273340		Acute and Chronic Pain	Phase 1

Pfizer Pipeline – May 9, 2013 (cont'd)

Therapeutic Area	Compound Name	Mechanism of Action (Phase 3 through regulatory approval)	Indication	Phase
Oncology	dacomitinib (PF-00299804)	pan-HER Inhibitor	Previously Treated Advanced Non-Small Cell Lung Cancer	Phase 3
	►dacomitinib (PF-00299804)	pan-HER Inhibitor	1st Line Non-Small Cell Lung Cancer	Phase 3
	Xalkori (crizotinib)	c-MET-ALK Inhibitor	ALK-Positive 1st and 2nd Line (supports potential full approval in the U.S.) Non-Small Cell Lung Cancer, *Cancer	Phase 3
	Inlyta (axitinib)	VEGF Tyrosine Kinase Inhibitor	Renal Cell Carcinoma Adjuvant (Asia only)	Phase 3
	Sutent	Multiple Tyrosine Kinase Inhibitor	Renal Cell Carcinoma Adjuvant	Phase 3
	palbociclib (PD-0332991)	CDK 4,6 Kinase Inhibitor	1st Line Advanced Breast Cancer, *Cancer	Phase 3
	inotuzumab ozogamicin		Aggressive Non-Hodgkin Lymphoma (Biologic)	Phase 3
	inotuzumab ozogamicin		Acute Lymphoblastic Leukemia (Biologic)	Phase 3
	Inlyta (axitinib)		Liver Cancer	Phase 2
	dacomitinib (PF-00299804)		Cancer	Phase 2
	PF-05212384		Endometrial Cancer, *Cancer	Phase 2
	PF-03084014		Cancer	Phase 1
	PF-03446962		Cancer (Biologic)	Phase 1
	PD-0325901		Cancer (in combination with PF-05212384)	Phase 1
	PF-05082566		Cancer (Biologic)	Phase 1
	PF-04449913		Acute Myelocytic Leukemia	Phase 1

New Molecular Entity

New Indication or Enhancement

* Note: Additional indications in Phase 1

Pfizer Pipeline – May 9, 2013 (cont'd)

Therapeutic Area	Compound Name	Mechanism of Action (Phase 3 through regulatory approval)	Indication	Phase
Vaccines	MnB rLP2086 (PF-05212366)		Adolescent and Young Adult Meningitis B	Phase 3
	ACC-001 (PF-05236806)		Alzheimer's Disease	Phase 2
	4-Antigen Staphylococcus Aureus Vaccine (SA4Ag) (PF-06290510)		Staph Aureus	Phase 2
	PF-05402536		Smoking Cessation	Phase 1
	PF-06425090		Clostridium Difficile Colitis	Phase 1
	PF-06444752		Asthma	Phase 1

New Molecular Entity

New Indication or Enhancement

Pfizer Pipeline – May 9, 2013 (cont'd)

Therapeutic Area	Compound Name	Mechanism of Action (Phase 3 through regulatory approval)	Indication	Phase
Other Areas of Focus (Rare Diseases)	tafamidis meglumine	Transthyretin (TTR) Dissociation Inhibitor	Transthyretin familial amyloid polyneuropathy (U.S.)	Registration
	PF-06460031 (GMI-1070)		Vaso-occlusive crisis associated with Sickle Cell Disease	Phase 2
	PF-05280602		Hemophilia (Biologic)	Phase 1
	PF-06252616		Muscular Dystrophies (Biologic)	Phase 1
	PF-06687859		Spinal Muscular Atrophy	Phase 1
Other Areas of Focus (Biosimilars)	PF-05280586		Rheumatoid Arthritis (Biosimilar)	Phase 1
	PF-05280014		Metastatic Breast Cancer (Biosimilar)	Phase 1
Other Areas of Focus	bazedoxifene-conjugated estrogens	Tissue Selective Estrogen Complex	Menopausal Vasomotor Symptoms (U.S.) / (EU)	Registration
	Viviant	Selective Estrogen Receptor Modulator	Osteoporosis Treatment and Prevention (U.S.)	Registration
	Zithromax/chloroquine	5-OS Ribosome Inhibitor	Malaria	Phase 3
	bosutinib		Autosomal Dominant Polycystic Kidney Disease	Phase 2
	PNU-100480		Tuberculosis	Phase 2

New Molecular Entity | New Indication or Enhancement | Biosimilar

Projects Discontinued from Development since February 28, 2013

Compound Name	Mechanism of Action (Phase 3 through regulatory approval)	Indication	Phase
RN6G (PF-04382923)		Age-Related Macular Degeneration (Biologic)	Phase 2
PF-04605412		Cancer (Biologic)	Phase 1
CVX 096 (PF-04856883)		Diabetes Mellitus-Type 2 (Biologic)	Phase 1
CVX 060 (PF-04856884)		Renal Cell Carcinoma, *Cancer (Biologic)	Phase 1

New Indication or Enhancement

New Molecular Entity

* Note: Additional indications in Phase 1